In particular, few reports have examined this for CRC, and the only report on the efficacy of WEE1 inhibitors as single agents is the report on the clinical trial [9], which did not examine the difference in the efficacy of WEE1 inhibitors depending on the presence or absence of p53 or KRAS mutations. Here, KRAS is linked to colorectal carcinoma.